Establish a dialog with entities holding currently inaccessible toxicogenomic data to evaluate options for increasing the availability of data.
Regulatory government agencies (including EPA and the Food and Drug Administration) should consider appropriate ways to address the following disincentives to industry generation and public submission of data that could be used to populate public databases: additional costs of testing; concerns about reporting requirements of the TSCA and the Federal Insecticide, Fungicide, and Rodenticide Act; concerns about competitors’ use of toxicity data if they are made public; and concerns about the use of toxicogenomic data in tort liability cases.
Integrate data relevant to toxicogenomic screening of environmental chemicals into ongoing biomedical initiatives such as the National Institutes of Health Molecular Libraries initiative. Such data may include physicochemical characteristics, in vitro assay results such as cytotoxicity and receptor binding, and other screening-level types of data.
Ensure that the regulatory framework provides incentives, or at least removes disincentives, for premarket testing of chemicals.
Upon validation and development of adequate databases, integrate toxicogenomic screening methods into relevant current and future chemical regulatory and safety programs.